Wednesday, November 18, 2026

thumbnail

Sanger vs Illumina vs Nanopore: How DNA Sequencing Works


Which sequencing platform should you use? It sounds like a simple question, and it never is. Sanger, Illumina and Oxford Nanopore all read DNA, yet they go about it in completely different ways, and those differences decide which one is right for your question.

In this post I walk through the three, one at a time. Every technique gets a one-line explanation the first time it appears, so nobody is left behind, and at the end I suggest a practical way to choose between them. If you work with Plasmodium falciparum, I also point out where each platform helps and where it trips.

Sanger sequencing: the careful pioneer




Let's start where it all began. In 1977, Frederick Sanger, Steve Nicklen and Alan Coulson published a method for reading DNA that was faster and more accurate than anything before it, and they proved it on the genome of a small virus called bacteriophage φX174 (Sanger et al., 1977). Sanger shared the 1980 Nobel Prize in Chemistry for this body of work, and his method stayed the backbone of sequencing for about thirty years, right through the Human Genome Project.

How it works

Everything begins with a primer, a short piece of DNA that sticks to one defined spot on your template (the DNA you want to read). A polymerase, the enzyme that copies DNA, starts extending from that spot. This detail matters more than it looks. Because the primer binds at one known place, every new strand begins at exactly the same position, and only the far end differs from strand to strand. That is how we know where we are, and which direction we are reading: away from the primer, from the 5′ end toward the 3′ end of the new strand.

Now comes the clever part, called chain termination. Mixed in with the normal building blocks (dNTPs) is a small amount of special ones called dideoxynucleotides, or ddNTPs. A ddNTP is missing the 3′ hydroxyl group that the polymerase needs to attach the next base, so when one gets incorporated, copying stops dead. Because ddNTPs are scarce compared with normal dNTPs, the stop happens at a random position in each copy. Over millions of copies you end up with a fragment ending at every possible position: a nested set, all sharing the same start (the primer), each ending at a known base.

One tube or four? A little history

Here is something that confused me. In the original 1977 method, Sanger ran four separate reactions, one for each type of terminator, with radioactive labels, and loaded the products into four neighbouring lanes of a gel. (A fun detail: the cytosine terminator in that first paper was an arabinose analogue, araCTP, rather than ddCTP.) Many textbooks still draw it this way, and having that four-tube picture in my memory made the modern version confusing at first.

Today the reaction happens in a single tube. All four ddNTPs are present together, and each carries its own fluorescent dye, one colour per base. Since the last base of every fragment is colour-coded, the whole mixture can be loaded into one capillary and read in a single run. Same idea, a fraction of the pipetting.

Reading the result

The fragments are sorted by size using capillary electrophoresis. That sounds intimidating, but the idea is simple. DNA carries a negative charge, so when you apply an electric field across a hair-thin tube filled with gel, the DNA moves, and shorter pieces slip through faster than longer ones. As each fragment passes a detector, a laser excites its dye and the colour is recorded. The shortest fragment comes first, so the first colour is the base right after the primer, the second colour is the next base, and so on. The output is the chromatogram, a trace of coloured peaks with one peak per base.

Strengths and limits

Sanger reads run to roughly 700 to 1,000 bases, and accuracy is the best of the three platforms, around 99.99% in the clean middle of a read. The first 30 bases or so, and the tail end, are messier. Throughput is the catch: one fragment per reaction, or 96 or 384 in parallel at most. Think scalpel, not combine harvester.

That is why I still love it for jobs with a single target. Checking a plasmid (a small circular piece of DNA used as a cloning vector), confirming a CRISPR edit, genotyping one locus, verifying an amplicon, or validating a variant that another method flagged. For all of these it remains the gold standard.

Its blind spot is mixed templates. If two different sequences are in the tube, their peaks overlap and the chromatogram turns into soup. In malaria work, where one patient can carry several parasite genotypes at once, that is a real headache.

Illumina sequencing: the workhorse



If Sanger is the scalpel, Illumina is the factory. The technology began at a company called Solexa, and a landmark 2008 paper from that team showed the approach could produce an accurate human genome (Bentley et al., 2008). They sequenced a male Yoruba individual from Ibadan, Nigeria, reading short paired 35-base fragments to an average depth of more than 30x, and from that they characterised about four million single-nucleotide variants. It is rather lovely that a West African genome was the showpiece.

And here is a small twist of history. Two of the authors, John Milton and Clive Brown, list Oxford Nanopore Technologies as their present address in that very paper. Hold that thought, because we will meet their company again shortly.

How it works

Illumina uses sequencing by synthesis, which means you watch a polymerase build a new strand and record each base as it is added. First, the DNA is broken into fragments and given adapters, short pieces of known sequence on each end. The adapters let the fragments stick to a flow cell, a glass slide with tiny lanes whose surface is coated with matching anchor sequences.

One molecule on its own is far too faint to detect, so each fragment is copied in place into a tight cluster of identical molecules, using bridge amplification (or ExAmp on patterned flow cells). Thousands of identical strands shining together give the camera something it can see.

Then the cycles begin. Each cycle adds fluorescent, reversibly terminated nucleotides: bases that carry a dye and a removable block, so only one base can be added per round. The instrument images every cluster, cleaves off the dye and the block, and repeats. Newer instruments such as the NextSeq and NovaSeq use two-colour chemistry to speed this up. Reads are typically 50 to 300 bases long and are usually paired-end, meaning both ends of each fragment are sequenced, which makes it much easier to work out where a read belongs in the genome.

What it is good for

Accuracy is very high: better than Q30, which means fewer than 1 error in 1,000 bases (about 99.9%), and the errors are mostly substitutions, where one base is swapped for another. Output ranges from gigabases on a small MiSeq to multiple terabases per run on a NovaSeq X, at the lowest cost per base of the three platforms.

That scale powers whole genome sequencing (WGS) and exome sequencing, which reads only the protein-coding portion, roughly 1 to 2% of the genome. It also powers RNA-seq (reading which genes are active by sequencing RNA after converting it to DNA), ChIP-seq (finding where proteins bind DNA), amplicon panels (deep sequencing of PCR-amplified target regions), variant calling (finding where a sample differs from a reference) and population genomics.

Where it struggles

Short reads have blind spots. Repeats and structural variants (large rearrangements such as deletions, inversions and duplications) are hard to resolve, because a short piece of sequence cannot tell you where in a repetitive region it belongs. The same goes for highly variable gene families.

The chemistry brings its own gremlins. Amplification can cause GC bias (uneven coverage of GC-rich and AT-rich regions) and duplicates (PCR copies of the same original molecule). This is rough on AT-rich genomes like P. falciparum, where PCR-free or low-cycle library protocols help. Index hopping happens when the barcodes that label each sample swap onto the wrong one, causing crosstalk. Phasing errors occur when some molecules in a cluster fall out of step, so the signal blurs in later cycles.

Oxford Nanopore sequencing: the free spirit




Remember John Milton and Clive Brown? Oxford Nanopore Technologies took a completely different route. Its best-known moment came in 2015, when a team packed a genome surveillance laboratory into less than 50 kg of ordinary airline luggage and took it to Guinea during the West African Ebola epidemic. The sequencer at the heart of it, the MinION, weighs less than 100 grams. They began sequencing within two days of arriving, and they could produce results less than 24 hours after receiving a positive sample, with the sequencing itself taking as little as 15 to 60 minutes (Quick et al., 2016). Carrying the sequencer to the outbreak, instead of shipping samples to the sequencer, still strikes me as a wonderful idea.

How it works

Nanopore sequencing is different in kind. There is no synthesis step, and no amplification is needed: it reads a single native molecule of DNA or RNA. A motor protein, an enzyme that ratchets the DNA along, feeds a single strand through a protein nanopore embedded in a membrane, while a voltage drives ionic current through the pore. Each k-mer, a short stretch of a few bases sitting in the pore at that moment, disrupts the current in its own characteristic way. Neural-network basecallers, software that translates the current trace into A, C, G and T, turn that signal into sequence.

Reads, accuracy and scale

Read length is limited by your DNA, not by the chemistry. Reads run from a few hundred bases to well over a megabase if you can extract DNA that long. The Flongle and MinION are portable, the GridION is mid-scale, and the PromethION is built for high throughput. Per gigabase, it is still generally more expensive than Illumina at large scale.

Accuracy used to be the weak spot, and homopolymers (runs of the same base, such as AAAAAA) were especially hard. The Ebola team noted exactly this limitation in 2016 (Quick et al., 2016). Things have moved on. With the R10.4.1 pore and Kit 14 chemistry, Oxford Nanopore reports simplex reads (one strand read once) at Q20 or better, and duplex reads (both strands read and combined into one consensus) at about Q30 or higher (Oxford Nanopore Technologies, n.d.). Homopolymers and some systematic errors remain the hardest cases, and the platform is sensitive to DNA quality and contaminants, so extraction matters.

The superpowers

  • Ultra-long reads that span repeats and structural variants, which is why genomes assemble so well.
  • Direct RNA sequencing, which reads the RNA itself with no cDNA conversion and gives full-length isoforms (the different versions of a transcript made from a single gene).
  • Native detection of base modifications such as 5mC and 6mA, methyl tags on DNA that can influence gene regulation. The older approach, bisulfite conversion (a harsh chemical treatment), is not needed, which is welcome news because bisulfite damages DNA.
  • Real-time output, so you can stop the run when you have enough data.
  • Adaptive sampling, where the pore decides as it reads whether to keep or reject a molecule, enriching the targets you care about.
  • Portability, as the Ebola story shows.

Side by side

 SangerIlluminaOxford Nanopore
Read lengthAbout 700 to 1,000 bases50 to 300 basesA few hundred bases to over 1 Mb
Per-base accuracyHighest (about 99.99%)Very high (above Q30)Good and improving (Q20+ simplex, about Q30 duplex)
ThroughputVery lowVery highLow to high, scalable
Cost per baseHighestLowestGenerally higher than Illumina at scale
Best forValidating one targetVariant calling, expression, population dataAssembly, structural variants, modifications, field work
Main weaknessThroughput, mixed templatesShort reads, GC biasRaw error rate, sensitivity to DNA quality

Which one should you choose?

Ask what your question really needs. If you want to confirm one variant or one clone, reach for Sanger. If you need depth and breadth, such as a whole genome, an exome, or expression across thousands of genes, reach for Illumina. If you need to span repeats, find structural variants, read base modifications, or sequence in the field, reach for Nanopore.

Better still, think of them as a team rather than rivals. A common strategy is hybrid. Long reads (from Nanopore, or from PacBio HiFi, another long-read platform) scaffold the genome, meaning they order and join assembled pieces, and they resolve repeats. Illumina polishes the accuracy. Sanger confirms the key variants.

What this means for Plasmodium falciparum work

The P. falciparum genome is extremely AT-rich, at roughly 80% A and T overall, which makes it a stress test for any method that relies on amplification. That is why PCR-free or low-cycle Illumina libraries, and increasingly native nanopore reads, attract so much interest in malaria genomics. Mixed-genotype infections, common in high-transmission settings, will muddy a Sanger chromatogram but can be picked apart with deep short-read coverage. Highly variable, repetitive gene families such as the var genes are exactly where long reads earn their keep. And Sanger still has a place: confirming a single resistance-associated variant once another platform has pointed to it.

Watch the video

Prefer to watch rather than read? The video version will be on the Adwoa Biotech YouTube channel on Dec 17, 2026.

Related Content

References

Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. G., Hall, K. P., Evers, D. J., Barnes, C. L., Bignell, H. R., Boutell, J. M., Bryant, J., Carter, R. J., Cheetham, R. K., Cox, A. J., Ellis, D. J., Flatbush, M. R., Gormley, N. A., Humphray, S. J., . . . Smith, A. J. (2008). Accurate whole human genome sequencing using reversible terminator chemistry. Nature, 456(7218), 53–59. https://doi.org/10.1038/nature07517

Oxford Nanopore Technologies. (n.d.). Q20+ chemistry. https://nanoporetech.com/q20plus-chemistry

Quick, J., Loman, N. J., Duraffour, S., Simpson, J. T., Severi, E., Cowley, L., Bore, J. A., Koundouno, R., Dudas, G., Mikhail, A., Ouédraogo, N., Afrough, B., Bah, A., Baum, J. H. J., Becker-Ziaja, B., Boettcher, J. P., Cabeza-Cabrerizo, M., Camino-Sánchez, Á., Carter, L. L., . . . Carroll, M. W. (2016). Real-time, portable genome sequencing for Ebola surveillance. Nature, 530(7589), 228–232. https://doi.org/10.1038/nature16996

Sanger, F., Nicklen, S., & Coulson, A. R. (1977). DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences, 74(12), 5463–5467. https://doi.org/10.1073/pnas.74.12.5463

thumbnail

How to Load a Nanopore Flow Cell: 3 Simple Steps

 



Of all the steps in a nanopore run, loading the Flow Cell is the one that makes people hold their breath. You have spent hours on extraction, library prep and cleanup, and now everything depends on a few drops of liquid going through one small port. So how do you do it without introducing bubbles, wasting library, or damaging the pores?

The good news is that the whole procedure comes down to three steps. Once you understand why each one exists, it stops feeling like a high-wire act and starts feeling routine.

Step 1: Check for a small bubble under the cover

Before anything touches the Flow Cell, look closely at the area under the cover. Sometimes a small bubble hides there, and you want it gone before any liquid goes in. If you see one, set your pipette and gently draw back a small volume of about a few µl through the priming port. The bubble moves with the liquid and leaves the Flow Cell, so your priming mix has a clean path ahead of it.

Step 2: Prime the Flow Cell

Priming prepares the Flow Cell to receive your library, and it happens in three small movements.

  1. First load. Load 800 µl of the priming mix into the Flow Cell through the priming port, taking care not to introduce air bubbles. Then wait five minutes.
  2. Open the sample port. Gently lift the SpotON sample port cover to allow free flow of liquid for the next step.
  3. Second load. Load 200 µl of the priming mix through the priming port, and not through the SpotON sample port. Again, avoid air bubbles by leaving a small volume of liquid in the pipette tip.

A tip from Oxford Nanopore: for best results, perform the 200 µl flush immediately before loading the library into the Flow Cell. Timing it this way keeps the Flow Cell wet and ready, so there is no long gap between priming and loading.

Step 3: Load the library dropwise

Just before loading, mix your library gently by pipetting up and down. Then add 75 µl of sample to the Flow Cell through the SpotON sample port, one drop at a time. Make sure each drop flows into the port before you add the next. It is slow, and it can feel tedious, but patience here is what protects your run from bubbles.

Quick summary

Step What you load Where Volume
1. Remove bubble Draw back liquid Priming port A few µl
2a. First prime Priming mix Priming port 800 µl
2c. Second prime Priming mix Priming port 200 µl
3. Load library Library SpotON sample port, dropwise 75 µl

Watch the video

Video loading on the Adwoa Biotech Channel

Related Content

Reference

Oxford Nanopore Technologies. (n.d.). Flow Cell loading instructions. https://nanoporetech.com

Tuesday, November 10, 2026

thumbnail

CRISPR Types Explained: Class, Type and Subtype Made Simple


 

I will be honest with you. The first time I tried to make sense of CRISPR classification, I closed the paper with a headache. Roman numerals, capital letters, “Cas” followed by a number, and what seemed like a new name for every protein. Does it really have to be this complicated? The short answer is no. It looks far worse than it is, and once you see the logic behind it, the whole system falls into place.

In this post I will walk through how CRISPR-Cas systems are classified, what the classification is actually based on, and where the famous Cas9 protein fits in. Along the way I will explain every term as we meet it, so you can follow even if you have never opened a microbiology textbook.

A quick bit of history

The story starts in 1987, long before anyone dreamed of gene editing. A Japanese team led by Yoshizumi Ishino was sequencing a gene in Escherichia coli and noticed something odd next to it: short, repeated DNA sequences separated by unique stretches of DNA. Nobody knew what they were for. For years they remained a curiosity, a puzzle sitting quietly in bacterial genomes.

Then the puzzle began to grow. Similar repeats turned up in other bacteria, and in archaea too. In 2002, Ruud Jansen and colleagues gave them the name we use today, CRISPR (clustered regularly interspaced short palindromic repeats), and noticed that a set of genes always travelled alongside them. They called those genes cas, for CRISPR-associated.

The real breakthrough came in 2007. Rodolphe Barrangou and colleagues, working with the yogurt bacterium Streptococcus thermophilus, showed that these repeats act as an adaptive immune system. When a virus that infects bacteria (a bacteriophage, or phage) attacks, the bacterium can save a small piece of the phage DNA between its repeats. That saved piece is called a spacer. Next time the same phage arrives, the bacterium recognizes it and destroys it. A memory of past infections, written into the genome. Beautiful, isn’t it?

After that, the field exploded, and so did the number of different CRISPR systems being discovered. That is exactly why a classification was needed.

How common is CRISPR in the first place?

Before we sort the systems into boxes, a fair question: how many microbes have one? Genome surveys suggest that roughly 40% of sequenced bacterial genomes carry a CRISPR-Cas system, while about 85% of archaea do. Treat these as rough figures. Databases over-represent bacteria that are easy to grow or medically important, while the many bacteria we cannot culture in the lab are under-represented. CRISPR systems are also gained and lost frequently, so even two strains of the same species can differ. And the exact number shifts a little depending on how a survey defines a system, for example whether a lone CRISPR array without cas genes counts.

What is the classification based on?

Every CRISPR-Cas system does three basic jobs.

  • Adaptation: capturing new spacers from invaders. This is done by Cas1 and Cas2.
  • Processing: turning the CRISPR array into short guide RNAs, called crRNAs.
  • Interference: using a guide RNA to find the invader and destroy or disable it.

Cas1 and Cas2 are found in almost every system, so they cannot tell one system from another. Instead, the classification focuses on the interference step, and in particular on the effector module. The effector is the machinery that recognizes the target and deals with it. It is the part that makes each system different.

The classification then works as a hierarchy, like a family tree with three levels.

  1. Class is decided by the architecture of the effector: is it a team of several proteins or a single large protein?
  2. Type is decided by a signature gene, one diagnostic cas gene that is found only in that type.
  3. Subtype is decided by the finer details, such as extra accessory genes, how the genes are arranged in the locus (the stretch of DNA where they sit), and the evolutionary relationships between the proteins, which is called phylogeny.

Wait, is the effector just the cutter?

Mostly, but not quite. The effector does the whole interference job, and that includes finding the target as well as cutting it. In some systems one protein does both. In others, the two jobs are split between different parts.

Think of it this way. In some systems the effector is a Swiss army knife that finds and cuts. In others it is a crew, where some members locate the target and others do the cutting. The cutter is part of the effector, but it is not the whole story.

Class 1: the team players

Class 1 systems use a multi-subunit effector complex, meaning several Cas proteins assemble together into one machine. They make up roughly 90% of CRISPR loci found in nature.

TypeSignature geneTargetWhat to remember
ICas3dsDNAThe most common type overall. A complex called Cascade finds the target, then Cas3 shreds it.
IIICas10RNA, and DNA while it is being transcribedWorks only when the target is being transcribed. Uses small signalling molecules called cyclic oligoadenylates.
IVCsf1Not well understoodRare. Mostly found on plasmids and prophages, and often missing adaptation genes.

Type I is a lovely example of divided labour. Cascade is the finder: a guide RNA plus several Cas proteins that scan DNA for a match. Once Cascade locks on, it recruits Cas3, a protein that combines a helicase (an enzyme that unwinds DNA) with a nuclease (an enzyme that cuts nucleic acids). Cascade finds, Cas3 shreds. Type I also needs a short motif next to the target called a PAM (protospacer adjacent motif), which helps the system tell invader DNA from the bacterium’s own.

Type III works differently. Its complex recognizes RNA, and the Cas10 subunit makes cyclic oligoadenylate signals that switch on other nucleases such as Csm6. Because it needs the target to be transcribed, it checks that the invader is actively doing something before it strikes.

Class 2: the lone wolves

Class 2 systems use a single, large, multidomain protein that does everything the Class 1 team does. They are only about 10% of loci, but they are the stars of genome editing, precisely because one protein is so much easier to move into another cell than a whole complex.

TypeSignature geneTargetWhat to remember
IICas9dsDNANeeds a tracrRNA as well as the crRNA. Blunt cut. Two nuclease domains, HNH and RuvC.
VCas12dsDNA and ssDNARuvC nuclease only. Staggered cut. Cas12a needs no tracrRNA. Includes the miniature Cas12f.
VICas13RNATwo HEPN domains. Collateral RNA cleavage, which is the basis of SHERLOCK diagnostics.

A few of those words deserve a plain explanation. A tracrRNA (trans-activating CRISPR RNA) is a second RNA that Cas9 needs, alongside the crRNA, to become active. HNH and RuvC are the two nuclease domains of Cas9: each one cuts one strand of the DNA double helix. HEPN domains are the RNA-cutting parts of Cas13. And collateral cleavage means that after Cas13 finds its target, it keeps chopping up any nearby RNA, which can be harnessed as a detection signal in a diagnostic test.

Where does Cas9 live?

Cas9 is the signature protein of Type II, and Type II is a minority, roughly 5 to 10% of CRISPR-bearing genomes in most surveys. It is essentially a bacterial protein and is very rare or absent in archaea. It turns up mainly in Firmicutes and Proteobacteria, with scattered occurrences in Bacteroidetes, Actinobacteria, Spirochaetes and Cyanobacteria. Even within one genus it is patchy, so having Cas9 in one species tells you little about its relatives.

The subtypes are defined by accessory genes.

  • II-A carries Csn2 alongside Cas9. Examples include Streptococcus pyogenes (the source of SpCas9, the workhorse of the lab), S. thermophilus, Staphylococcus aureus (SaCas9), Listeriaand some Lactobacillus and Enterococcus species.
  • II-B carries Cas4. Examples include Legionella pneumophila and Francisella novicida.
  • II-C has only Cas1 and Cas2 alongside Cas9. It is the most widespread and diverse subtype, found in Neisseria meningitidis, Campylobacter jejuni, Pasteurella multocida, Treponema denticola, Corynebacterium diphtheriae and others.

Why does anyone care about the different versions? Because Cas9 proteins from different species, called orthologs, differ in size and in the PAM they recognize. SpCas9 is about 1,368 amino acids long and recognizes NGG. SaCas9 is smaller, at about 1,053, and recognizes NNGRRT. CjCas9 is smaller still, at about 984. Smaller orthologs are attractive when you need to fit the editor inside a delivery vehicle with limited space, such as an AAV (adeno-associated virus).

A simple way to remember it all

If the Roman numerals still feel slippery, try this.

  • Class tells you one protein or many.
  • Type is decided by a CRISPR system’s signature protein. A CRISPR system with Cas3 is Type I, one with Cas9 is Type II, one with Cas10 is Type III, one with Csf1 is Type IV, one with Cas12 is Type V, and one with Cas13 is Type VI.
  • Subtype is the letter after the numeral, such as II-A or II-C, and it tells you which variant, mainly from the accessory genes.

And a handy shortcut for spotting Type II: if the system needs a tracrRNA, you are probably looking at Cas9 and not Cas12.

The classification keeps growing

This is not a finished map. Class 2 effectors appear to have evolved from nucleases carried by mobile genetic elements. Cas12, for example, is thought to descend from TnpB-like proteins found in transposons (jumping genes). Each time researchers discover a new family of these proteins, the classification has to stretch to fit it. The 2020 update recognized 2 classes, 6 types and 33 subtypes, and those numbers have likely moved since. More types have since been proposed, which tells you how much of the microbial world is still unexplored.

Why this matters for you

If you work in a lab, or are heading towards one, this classification is more than trivia. It explains why Cas9 needs a tracrRNA and Cas12a does not. It explains why Cas13 is used for RNA detection while Cas9 is used for DNA editing. And it points to where the next generation of tools might come from: the small, strange and little-studied systems sitting in the bacteria we have not yet learned to grow.

Watch the video

Prefer to see it explained? The Adwoa Biotech YouTube channel has a video on the basics of CRISPR-Cas9, covering the history, guide RNAs, PAM sequences and the sickle cell example. https://youtu.be/VlbGQiB83-Y?si=0gnpCu2gmcYZN0cR

Key takeaways

  • CRISPR-Cas systems are classified mainly by their effector module, the machinery that recognizes and deals with the target.
  • Class 1 uses a multi-subunit complex (Types I, III, IV). Class 2 uses a single protein (Types II, V, VI).
  • The type is set by a signature gene, and the subtype by accessory genes, locus organization and phylogeny.
  • Cas9 is the signature protein of Type II, found in a minority of CRISPR-bearing bacteria.
  • The effector is the whole interference machinery, not just the cutter.

References

Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science, 315(5819), 1709-1712. https://doi.org/10.1126/science.1138140

Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987). Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of Bacteriology, 169(12), 5429-5433. https://doi.org/10.1128/jb.169.12.5429-5433.1987

Jansen, R., van Embden, J. D. A., Gaastra, W., & Schouls, L. M. (2002). Identification of genes that are associated with DNA repeats in prokaryotes. Molecular Microbiology, 43(6), 1565-1575. https://doi.org/10.1046/j.1365-2958.2002.02839.x

Makarova, K. S., Haft, D. H., Barrangou, R., Brouns, S. J. J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F. J. M., Wolf, Y. I., Yakunin, A. F., van der Oost, J., & Koonin, E. V. (2011). Evolution and classification of the CRISPR-Cas systems. Nature Reviews Microbiology, 9(6), 467-477. https://doi.org/10.1038/nrmicro2577

Makarova, K. S., Wolf, Y. I., Iranzo, J., Shmakov, S. A., Alkhnbashi, O. S., Brouns, S. J. J., Charpentier, E., Cheng, D., Haft, D. H., Horvath, P., Moineau, S., Mojica, F. J. M., Scott, D., Shah, S. A., Siksnys, V., Terns, M. P., Venclovas, C., White, M. F., Yakunin, A. F., ... Koonin, E. V. (2020). Evolutionary classification of CRISPR-Cas systems: A burst of class 2 and derived variants. Nature Reviews Microbiology, 18(2), 67-83. https://doi.org/10.1038/s41579-019-0299-x

Shmakov, S., Smargon, A., Scott, D., Cox, D., Pyzocha, N., Yan, W., Abudayyeh, O. O., Gootenberg, J. S., Makarova, K. S., Wolf, Y. I., Severinov, K., Zhang, F., & Koonin, E. V. (2017). Diversity and evolution of class 2 CRISPR-Cas systems. Nature Reviews Microbiology, 15(3), 169-182. https://doi.org/10.1038/nrmicro.2016.184

Related Content

Monday, November 9, 2026

thumbnail

How PCR Tells Plasmodium Species Apart: Reading the Bands

How PCR Tells Plasmodium Species Apart: Reading the Bands


Image credit: @ATinyGreenCell 


I was looking at a photo of an agarose gel the other day. A ladder ran down each end, and between the two ladders sat a row of lanes, each with a bright band at a different height. My first thought was a lazy one: the bands must differ because we picked different primers for each lane, so we are really just labelling the result ourselves. Is the species written into the band, or are we writing it there?

The honest answer is a bit of both, and untangling the two is the whole point of this post. Once you see how the pieces fit, species-specific PCR stops looking like a magic trick and starts looking like good, careful design.


Figure: illustrative agarose gel with a DNA ladder (L) at each end and sample lanes between them. This image is for illustration only and does not show real Plasmodium data.

A band tells you size, and nothing else

Let's start with what a gel actually shows. When PCR copies a stretch of DNA, the product is called an amplicon, which simply means a copy of the target region made in large numbers. When you run that product through an agarose gel, shorter pieces travel farther and longer pieces lag behind. The ladder is a mix of DNA pieces of known lengths, so you can read off roughly how long your own band is.

That is all. A band has no species tag attached to it. It tells you how long the DNA is, and it tells you that the reaction found something to copy. Everything else, including the species name, comes from knowing which primers went into that tube.

Where the real differences live: the 18S rRNA gene

Now for the inherent part. Most species-specific Plasmodium PCR targets the 18S ribosomal RNA gene, often written 18S rRNA or SSU rRNA (small subunit ribosomal RNA). Ribosomes are the machines that build proteins, every cell needs them, and so every Plasmodium species carries this gene. That is why it makes such a handy target. It is also present in several copies per genome, roughly five to seven, which means there is more starting material to find and the test is more sensitive.

Here is the key feature. Along the length of this gene, some stretches are conserved, meaning they are almost identical in every species because changing them would damage the ribosome. Other stretches are variable, meaning evolution has been free to let them drift, so they differ from species to species. Picture a sentence in which most words are the same across four related languages but a few words are different in each. Those few words are what let you tell the languages apart.

These differences are real and built into the parasites. Nobody put them there. Primer design simply takes advantage of them.

Layer one: primers that can read the difference

A primer is a short piece of synthetic DNA, usually around 20 to 30 bases, that sticks to a matching sequence on the template and gives the polymerase a place to start copying. The sticking step is called annealing. The polymerase is the enzyme that builds the new DNA strand, and it can only add bases to the free end of a primer, known as the 3' end (said "three prime").

This is where specificity is won or lost. If the 3' end of the primer matches the template perfectly, the polymerase extends it and copying begins. If the very last base or two do not match, standard Taq polymerase, which has no proofreading ability, extends poorly or not at all. So designers place the 3' end of a species-specific primer right on a base that differs between species, and then use a stringent annealing temperature, meaning a temperature high enough that imperfect matches fall off. The result: the primer pair works on its own species and stays silent on the others.

That is the inherent layer. Without real sequence differences in the gene, there would be nothing for the primers to read.

Layer two: why the bands sit at different heights

Now back to my gel. If every species-specific pair worked on the same gene, why would the bands land at different heights?

Because in the classic assay each species gets its own forward and reverse primer pair, and each pair sits at a different position within the target region. Different positions mean different distances between the two primers, and that distance is the size of the product. This is where my original suspicion was partly right. The sizes are largely a consequence of where we chose to put the primers.

The widely used method is nested PCR, described by Snounou and colleagues (1993). Nested simply means two rounds. In the first round, genus-level primers sit in conserved regions and copy a long fragment from any Plasmodiumspecies present, around 1,100 bp in the commonly cited version of the protocol. A bp, or base pair, is the unit we use to count DNA length. In the second round, a small amount of that first product is moved into fresh tubes, one for each species, each with its own species-specific pair. The first round boosts sensitivity, and the second round supplies the species identity.

Species

Species-specific primer pair

Approximate product size

P. falciparum

rFAL1 and rFAL2

205 bp

P. vivax

rVIV1 and rVIV2

120 bp

P. malariae

rMAL1 and rMAL2

144 bp

P. ovale

rOVA1 and rOVA2

about 800 bp

Sizes are as commonly reported; a few papers give slightly different values for P. malariae, and P. ovale is now split into two species (curtisi and wallikeri) with a variant primer set for the second.

So a 120 bp band in the P. vivax tube and a 205 bp band in the P. falciparum tube are not the parasites announcing themselves in different sizes. They are the product of a careful design, in which sequence differences decide which pair works and primer placement decides how big the product is.

A small piece of history

Malaria parasites were first seen under the microscope by Alphonse Laveran in 1880, and for more than a century the blood smear stained with Giemsa remained the everyday way to name the species. It still is the front line in many clinics. Yet microscopy struggles when parasite numbers are low, when a mixed infection hides one species behind another, or when the smear is read by a tired eye at the end of a long shift.

PCR changed that. The Snounou paper appeared in 1993, the very year Kary Mullis received the Nobel Prize in Chemistry for inventing the technique. Within a few years, nested PCR had revealed something microscopy kept missing: mixed infections were far more common than anyone had assumed.

When size is the difference, and when it is not

In nested PCR, size is mostly a design choice. In other formats, size reflects a real difference in the DNA. If two species share the same primers but one has an insertion or deletion between them, the amplicons come out different lengths, and the gel shows it directly.

And some methods drop the gel altogether. In real-time PCR (qPCR), a fluorescent probe, a short DNA piece that glows only when it binds its exact target, reports which species is present. Different probes can carry different coloured dyes, so several species can be read in one tube. Another trick is melt curve analysis: after amplification you slowly heat the product, and the temperature at which the double strand falls apart depends on its sequence and GC content, which differs between species. Same idea, different readout.

What can go wrong

A few cautions are worth putting in any honest write-up of this method.

  • Controls matter. A positive control for each species and a no-template control (a tube with water instead of DNA) tell you whether a band is trustworthy or just contamination.
  • Isolates vary. A mutation under a primer can cause a false negative, so primers should be checked against parasites from the region where you work.
  • Mixed infections can be missed. When one species is far more abundant, it can outcompete the others during amplification, which is a good reason to run separate species-specific reactions.
  • Close relatives blur. Some closely related species are nearly identical at 18S, so a primer pair may not separate them. P. knowlesi also needs its own dedicated primer set, since the four-species panel above was not built for it.

The take-home

So, to answer my own question. The species is not written into the band height. It is written into the DNA sequence, and primers read it. The band height is something we then choose through primer placement, so that the answer is easy to read on a gel. Inherent differences decide who gets amplified, and design decides where the band lands.

Next time you look at a gel, ask two questions. What did the primers go looking for? And how far apart did we place them? Those two answers explain nearly every band on the picture.


Related content

References

Snounou, G., Viriyakosol, S., Zhu, X. P., Jarra, W., Pinheiro, L., do Rosario, V. E., Thaithong, S., & Brown, K. N. (1993). High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Molecular and Biochemical Parasitology, 61(2), 315-320. 

thumbnail

Gene Editing Delivery: Why Virus-Like Particles Matter Now

Credit: Feng Zhang

 

The scissors are ready, the courier is not

For years the big question in gene editing was whether we could cut DNA precisely. We can. CRISPR-Cas9, base editors and prime editors are real tools that work in real cells, and the first CRISPR medicine is already approved. So the question has quietly changed into something less glamorous: how do we get these tools into the right tissue of a human body?

It matters because most diseases misbehave in one particular tissue. A liver problem needs the editor in the liver. A blood disorder needs it in blood stem cells. An editor that lands in the wrong place does nothing useful at best, and causes trouble at worst. Cutting is the solved part. Delivery is where a lot of the field is stuck right now.

Take the cells out, or go inside the body?

The approved route is the easy one. Casgevy, from CRISPR Therapeutics and Vertex, treats sickle cell disease and transfusion-dependent beta-thalassemia. Doctors collect blood stem cells (CD34-positive cells) from the patient, and in the lab the Cas9 protein and its guide RNA are pushed into those cells with a short electric pulse called electroporation. The edited cells then go back to the patient. This is ex vivo editing, which simply means editing outside the body, and it works well because the cells sit in a dish where you control everything.

The price of that control is cost and complexity. You need a specialised hospital, a conditioning regimen, and a long stay. Hence the dream of in vivo editing: one injection in an ordinary clinic, and the patient's own tissue is reprogrammed. In parts of West Africa where sickle cell disease is common, the gap between a specialised transplant centre and a local clinic is not a technicality. It decides who can be treated at all.

A quick tour of the delivery vehicles

AAV. Adeno-associated virus is the workhorse of gene therapy, and its problem is room. It carries only about 4.7 kilobases of DNA, and a Cas9 gene plus a guide RNA plus the control elements to run them usually overshoots that. AAV DNA also sits in the nucleus as an episome, a small ring of DNA separate from your chromosomes. It is stable, and it only fades as cells divide. For a nuclease that is the wrong rhythm, because the longer Cas9 hangs around, the more chances it has to cut places it was never meant to cut.

Lentivirus. Lentiviral vectors hold roughly 8 to 10 kilobases, enough for editing tools, and they have a proven track record in CAR T cell therapies for blood cancers. The catch is that they integrate into your chromosomes. A scissors gene stitched into the genome keeps making scissors. Lentiviruses are usually given a borrowed coat protein in a process called pseudotyping, and the most popular coat, VSV-G, is about to become a main character.

Lipid nanoparticles (LNPs). These are tiny fat bubbles that carry RNA. Injected into the bloodstream, they pick up a protein called ApoE and are swallowed by liver cells through the LDL receptor route. The cargo then has to escape the endosome, the little bubble the cell wraps around anything it swallows, before it can do anything. That is why LNPs love the liver, and why getting them anywhere else is hard.

Intellia's nexiguran ziclumeran (nex-z) is the flagship example. It uses an LNP to deliver CRISPR components that switch off the TTR gene in the liver, as a one-time treatment for transthyretin amyloidosis. People sometimes call this a liver disease, but it is really a body-wide one: the liver is simply the factory that makes the misfolded protein.

It is also a useful reminder that liver delivery is not risk free. In October 2025 the FDA paused the nex-z phase 3 trials after a patient developed Grade 4 liver enzyme elevations and raised bilirubin, and later died. Intellia pointed to complicating comorbidities, and the holds were lifted in early 2026 with enhanced liver monitoring added. The lesson I take from it: a vehicle that goes to the liver by default is both a gift and a liability.

Why a short stay is a feature

The ideal editor does its job and leaves. You want a tight window in which the nuclease is active, enough to make the intended cut and not so long that it wanders. This is the real appeal of delivering the editor as a protein rather than as a gene. A protein is already working the moment it arrives, and the cell breaks it down within a short time. No DNA means nothing to integrate and nothing to keep expressing.

How do you deliver a protein to a cell without a gene? That is where virus-like particles come in.

Enter the virus-like particle

A virus-like particle (VLP) is a virus shell with the dangerous parts removed. It keeps the outer membrane and the structural proteins that let a virus dock, enter a cell and release its cargo, but it carries no viral genome, so it cannot replicate or integrate. Picture a delivery van wearing a courier's uniform: it knows how to find the right door and hand over the parcel, but it has no way of building new vans.

The engineering in David Liu's lab turned this into something practical. In their engineered VLPs (eVLPs), the editor protein is fused to a retroviral structural protein called Gag. When the particle assembles and buds out of a producer cell, it traps the editor together with its guide RNA as a ready-made ribonucleoprotein, or RNP, which is just the protein and RNA already bound to each other. A built-in protease then cuts the editor free inside the particle. In the 2022 Cell paper, eVLPs delivering a base editor achieved about 63% editing of the Pcsk9 gene in mouse liver, and a single injection partially restored vision in a mouse model of Leber congenital amaurosis.

So a VLP borrows from both worlds. It has the viral talent for getting into cells and releasing cargo, and the LNP-like virtue of leaving no genetic footprint.

The coat decides the address

The protein on the surface of the particle decides which cells it can enter. VSV-G (vesicular stomatitis virus glycoprotein) is a favourite because it is superb at binding cells and triggering fusion with the endosome. But its tropism, meaning the range of cells it can enter, is very broad. That is brilliant in a lab dish and a headache in medicine, where you want a particle that goes to a chosen cell and not everywhere.

The fix is a two-step trick. First, mutate VSV-G so that it no longer binds its natural receptors while keeping its ability to fuse, giving a version called VSVGmut. Second, display an antibody fragment on the particle surface, a single-chain variable fragment (scFv), to supply the address. The glycoprotein opens the door, and the antibody fragment tells the particle which door to knock on.

Jennifer Doudna's group, with Jennifer Hamilton as first author, built on this idea with enveloped delivery vehicles (EDVs). In a culture test with a mix of cells that did and did not carry the B cell marker CD19, CD19-targeted EDVs carrying Cas9 knocked out the B2M gene in up to 74% of target cells, with little to no editing in bystander cells. In mice with a humanised immune system, EDVs went on to generate gene-edited CAR T cells in vivo, with no off-target delivery to liver hepatocytes. That last detail is what caught my eye, because the liver is exactly where most delivery vehicles end up. Hamilton and Doudna later co-founded Azalea Therapeutics, whose lead program is a CD19-targeted in vivo CAR T therapy heading toward the clinic.

Where do VLPs stand in the clinic?

As of November 2026, and to my knowledge, no VLP-delivered nuclease or base editor has been given to a patient. The closest example is Ensoma's EN-374, which uses VLPs to deliver a working copy of the CYBB gene to blood stem cells inside the body, for X-linked chronic granulomatous disease. That is gene addition rather than gene editing, but it is billed as the first in vivo blood stem cell gene insertion therapy in the clinic, and the first participant's safety data were presented in May 2026. If it stays safe, it tells regulators something useful about VLPs in general.

An old idea with a new job

VLPs were doing medicine long before CRISPR. The hepatitis B vaccine, licensed in 1986, is built from hepatitis B surface antigen that assembles into virus-like particles with no genome inside, and the HPV vaccines later followed the same logic. The immune system sees a convincing virus shape, builds memory, and nothing infectious was ever in the vial. What is new is not the particle. It is the idea of loading it with an editor and putting an address label on the outside.

What I am watching

I like this story because it is gloriously unfinished. Much of the current work is careful tinkering: the linkers that hold the antibody fragment on the surface, the glycoprotein mutations, the way the editor is packed inside. Three things will tell us whether VLPs grow up. First, clinical data from a VLP-delivered editor. Second, whether the targeting holds up in larger animals and not just mice. Third, whether production, which relies on transfected producer cells much like lentiviral manufacturing, can scale.

If they do, the next question will not be whether we can edit a gene, but which cell we choose to send the courier to.

Watch the video

This post is adapted from the third video in Kevin Curran's gene editing delivery series, with corrections and updates built in: https://www.youtube.com/watch?v=97EpLp1Crf8

Related content

  • CRISPR-Cas9 basics: guide RNA, PAM and the sickle cell example
  • Specificity vs sensitivity in CRISPR diagnostics: cry wolf, miss wolf
  • Treatments that came from CRISPR

References

Banskota, S., Raguram, A., Suh, S., ... Liu, D. R. (2022). Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell, 185(2), 250-265.e16. https://doi.org/10.1016/j.cell.2021.12.021

Ensoma. (2026, May). Ensoma to present clinical safety data from first participant dosed with in vivo HSC engineering therapy at ASGCT Annual Meeting [Press release]. https://www.biospace.com/press-releases/ensoma-to-present-clinical-safety-data-from-first-participant-dosed-with-in-vivo-hsc-engineering-therapy-at-asgct-annual-meeting

Hamilton, J. R., Chen, E., Perez, B. S., Sandoval Espinoza, C. R., Kang, M. H., Trinidad, M., ... Doudna, J. A. (2024). In vivo human T cell engineering with enveloped delivery vehicles. Nature Biotechnology, 42(11), 1684-1692. https://doi.org/10.1038/s41587-023-02085-z

Intellia Therapeutics. (2026, January 27). Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE-2 Phase 3 clinical trial in ATTRv-PN [Press release]. https://ir.intelliatx.com/node/12431

Intellia Therapeutics. (2026, March 2). Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM [Press release]. https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/d101756dex992.htm


About

Search This Blog

Powered by Blogger.

Sanger vs Illumina vs Nanopore: How DNA Sequencing Works

Which sequencing platform should you use? It sounds like a simple question, and it never is. Sanger, Illumina and Oxford Nanopore all read D...

About Me

My photo
Adwoa Biotech Tools and Techniques Hub offers clear, practical explanations of essential molecular biology and biotechnology methods. Learn PCR primer design, cDNA synthesis, cloning strategies, nucleic acid purification, CRISPR delivery innovations, data analysis concepts, and everyday lab skills. Enjoyed the tutorial, connect with me on YouTube for video content on these topics: @adwoabiotech